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Summary
This mini-review will focus on the management of a patient
with bisphosphonate-associated osteonecrosis (BON). In or-
der to review the subject the authors report a case of a patient
with prostate cancer and metastatic bone disease who was
treated with zoledronic acid. Prior to cancer the patient was
treated with risedronate for osteopenia but had discontinued
this treatment when cancer was diagnosed. During the de-
scription of each aspect of the case, a discussion of the ratio-
nale used for the case management is presented with support
of the available literature. Aspects of interest include the diag-
nosis of BON, the risk factor for BON for this particular pa-
tient, the decision making process for the management of
acute and long-term oral cavity problems, and the introduc-
tion of high intensity laser therapy to help control pain and re-
duce infection and local bacterial load. 
KEY WORDS: bisphosphonates, osteonecrosis, complication, treatment,
laser therapy.
Introduction
Medical advancements in the area of cancer and osteoporosis
have been saving lives and improving the quality of life for mil-
lions of people around the world. This is in part due to the rela-
tively recent development of medications like the bisphospho-
nates to counter bone and mineral loss resulting from metastat-
ic bone disease, hypercalcemia of malignancy, osteopenia and
osteoporosis, and Paget’s disease of the bone (1, 2). However,
as it is discussed in this issue of the Journal, nothing comes
without a price (3). The recent description of bisphosphonates
associated osteonecrosis (BON), an oral complication associ-
ated with the use of either the intravenous or the oral formula-
tions, raised a number of questions and concerns on determin-
ing the best protocol to treat a patient with such disease (4-9).
In this mini-review we will report a case of BON in a patient
with metastatic prostate cancer who is under current manage-
ment by our team at Nova Southeastern University (NSU) Col-
lege of Dental Medicine. In addition to the management proce-
dures used in this particular case we will also discuss how we
made the diagnosis of BON, the specific risk factors present in
the patient’s history and how we are maintaining the patient
with a reasonable quality of life. Furthermore, new information
will be provided regarding the use of high intensity laser thera-
py to assist in the control of pain and secondary infection asso-
ciated with BON.
Case report
SV, 75 years old male, was referred to our clinic in March of
2006 by his periodontist for evaluation of implants on the right
maxilla. The chief complaint was pain and discomfort. The pa-
tient first experienced severe pain on the upper right maxilla in
October of 2005. Not being able to see a dentist at the time be-
cause it was in the middle of the hurricane season that affected
South Florida, he was given a prescription for aspirin over the
phone. Pain did not subside. He finally was seen by an en-
dodontist who diagnosed the problem as being the result of a
“bad root canal filling” of tooth # 5. The endodontic retreatment
of tooth # 5 (right maxilla) was performed following all standard
procedures but did not resolve the pain and chronic infection. A
paraendodontic (apicoectomy) surgery with open flap followed
with the goal of “cleaning” the periapical area around tooth # 5.
This procedure also did not help the control of either the pain
or the infection. During and after both procedures the patient
was treated with per oral penicillin. The patient was then re-
ferred to the periodontist who had originally placed the dental
implants for evaluation of the area of teeth #s 3 (implant), # 4
(implant) and #5 (natural tooth). After the consultation with the
periodontist the patient was informed that he needed the help
of an oral medicine professional, and was referred to NSU oral
medicine clinic. 
Medical History - The medical history revealed a diagnosis of
prostate cancer in 1994. The patient was treated with total
prostatectomy and was given only 4 years to live. During peri-
odic follow-ups a PSA elevation was detected. This required
treatment with external beam radiation therapy to the pelvic
area and back. The patient was also started on chemotherapy
and hormone therapy, which he continues to receive in variable
cycles of treatment until today. His medications over the years
included docetaxel, goserelin, and bicalutamide. Zoledronic
acid intravenous infusion monthly was started on 05/26/05 and
discontinued on 02/05/2006 (9 months total time), and was ad-
ministered due to metastatic bone disease. The patient was al-
so diagnosed with osteopenia sometime ago but could not re-
call precisely. He had used risedronate per oral for years to
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treat the osteopenia but was off the drug for several years. He
denied the use of tobacco and alcohol. Other than these two
medical problems, prostate cancer and osteopenia, the patient
was well, and was proud to say that he exercised regularly,
had good nutritional habits, and good attitude towards life and
the success of the treatment of his prostate cancer. The only
problem he had was the pain and infection in his mouth that
could not be controlled and that were changing his quality of
life.
Dental History - His oral hygiene habits included brushing and
flossing regularly and the use of mouthrinses with peroxide-
baking soda mix. The patient had had extensive dental work in
the past and was maintaining relatively good oral hygiene. 
Physical examination - The extraoral examination revealed
no visible face, head, or neck pathology. There was no evi-
dence of swelling or deformity. However, the area lateral to the
nose and infra-orbital on the right side of the face was sensitive
to palpation. Intraorally, an area of swelling and erythema, buc-
cal and palatal, around teeth/implants #s 3, 4 and 5 could be
observed (Fig. 1). The area was tender upon palpation and
percussion. In the buccal attached gingival toward the apical
area of the referred teeth/implants there were two areas of fis-
tulation from where a collection of purulent secretion were evi-
dent. A scar on the mesial-buccal attached gingiva of # 5 was
also present, indicating the area of the incision where the previ-
ous surgical procedure had been done. Teeth in the affected
area where non-depressible and presented no mobility. Tooth
# 5 was endodontically treated and #s 3 and 4 were implant-
supported crowns. Periodontal pockets in the area were
greater than 3 mm deep especially around teeth #s 4 and 5
where pocket depths ranged from 4-8 mm. There was no visi-
ble area of exposed necrotic bone observed at this time. The
rest of the oral mucosa showed no deviation from normal and
no other pathology in the oral cavity could be found. The radi-
ographic examination confirmed the clinical findings of severe
bone loss around # 3, #4 and #5 and the presence of periapical
pathology on the apex of tooth # 5 (Fig. 1). Less radiolucent ar-
eas were also noticed around the dental implant holding tooth
# 4 (Fig. 1).
Diagnosis of bisphosphonates-associated osteonecrosis
(BON) - Before we can effectively treat any type of pathology,
the most important aspect is to have a correct diagnosis. The
diagnosis of BON may be difficult and several aspects must be
considered. The clinical presentation has to fit the current defi-
nition for BON, and the patient must present risk factors so far
recognized as being indicative of an oral complication associat-
ed with the use of a bisphosphonate (10).
Definition (Cesar Migliorati, personal communication): We have
been using the following definition of BON divided in two
stages:
– stage I (the less common): The unexpected presence of
pain and infection anywhere in the oral cavity without clini-
cally visible exposed necrotic bone, that mimics dental dis-
ease, in a patient taking a bisphosphonate and who has not
received radiation therapy to the head and neck. The signs
and symptoms persist after the delivery of proper standard
dental care;
– stage II (the more common): The unexpected presence of
exposed necrotic bone anywhere in the oral cavity in a pa-
tient taking a bisphosphonate and who has not received ra-
diation therapy to the head and neck. The necrotic bone
persists for at least 6 to 8 weeks after the delivery of proper
standard dental care.
Patient characteristics and associated risk factors:
– a cancer patient with metastatic bone disease (multiple
myeloma, breast, prostate, lung);
– a patient with osteopenia or osteoporosis;
– a patient on bisphosphonate therapy for any reason;
– the use of intravenous bisphosphonate for a minimum of
several months to one year or the oral formulations for a
minimum of 3 to 4 years (zoledronic acid, pamidronate, clo-
dronate, alendronate, risedronate, ibandronate). The time
on therapy may vary from patient to patient (11);
– a patient with a chronic disease that may have been med-
icated with long-term corticosteroid therapy and who is un-
der oral bisphosphonate therapy for osteopenia or osteo-
porosis (9);
– it has also been suggested in the literature that patients with
diabetes are at higher risks for developing BON (12).
In the present case, the patient had long-term prostate cancer
with skeleton metastasis, took an intravenous bisphosphonate
(zoledronic acid) for 9 months and had previously used oral
risedronate for several years. His examination revealed that
there was no clinical evidence of exposed bone (except for the
fact that there were two fistulas: a 1 mm diameter mesial of #5
Figure 1 - Initial presentation. A. Observe area of swelling on the right maxillary arch on both buccal and palatal aspects (arrows). B. Periapical radi-
ograph of the area showing the presence of a radiolucency at the apex of tooth # 5 (arrow).
A B
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and a 2mm diameter in the area of # 4, with presence of puru-
lent secretion indicating active infection). In addition, there was
presence of persistent pain, severe periodontal and periapical
pathology, and poor response to routine standard dental/peri-
odontal procedures. All these aspects considered together lead
us to the working diagnosis of stage I BON. 
Patient management 
When the diagnosis of BON is made, management strategies
become a concern for the dental professional as there are not
well-established management guidelines that have a scientific
basis. The existing guidelines for the management of patients
with BON are based on the expert opinion of individuals who
have been dealing with this problem since it was first described
(4-6, 8, 9). Therefore, in the next step of management of the
present case we had to decide how to treat the acute symp-
toms, since the patient was complaining of severe pain, was
concerned about the fact that he had chronic infection and that
was changing his quality of life. The patient was informed
about the possible nature of this process and its relationship to
the bisphosphonates. He was also told that at this time we
could not determine what role the use of the two different bis-
phosphonates might have had in the case. We also told him
that because we could not find clinical evidence of exposed
necrotic bone, we were basing our diagnosis on his history of
bisphosphonate therapy and the fact that he had not respond-
ed to standard therapy for dental and periodontal problems
used for cases similar to the one he was presenting. We did
not want to obtain a bone biopsy for the confirmation of os-
teonecrosis because of the risk of creating an area of clinically
exposed bone and the risk of affecting the stability of the dental
implants. Because he had not taken an antibiotic in recent
weeks he was given a prescription for clindamycin 150 mg
(#60) to take 2 tabs tid (three times/day) for 10 days. The pa-
tient was also instructed to continue using the routine oral hy-
giene procedures and was given a prescription for chlorhexi-
dine 0.12% rinses to be used twice daily.
Two weeks later the patient returned to the clinic for a follow-up
consultation. He was feeling better with some improvement of
the sensitivity on the right side of the nose and face. The pain
went from unbearable and constant to less intense. He com-
pleted the course of 10 days on Clindamycin 300 mg tid with-
out complications. In the mean time, between the first and sec-
ond visits in our clinic, the patient saw a private endodontist
who wanted to perform a new endodontic retreatment on tooth
# 5 followed by a new flap surgery to assess the bone changes
in the area. We then discussed with both the patient and the
endodontist why we could not agree with this treatment proto-
col, once it had already been done without success, and the
risk of creating a defect with exposed necrotic bone. Both
agreed not to do the procedure. We based this decision on the
existing guidelines that recommend conservative, non-invasive
care (5, 9). At this visit the patient also informed us that the on-
cologist was considering using zoledronic acid again due to a
possible progress of bone disease. The patient was informed
that this was a medical, not a dental decision, and if there was
a medical indication for the use of zoledronic acid, he should
agree with the suggestion of the oncologist. The clinical exami-
nation of the area on the buccal vestibule of teeth #s 3-5 had
somehow improved (Fig. 2). The erythema was less intense
and there was little suppuration in only one of the two existing
fistulas, the more distal one (Fig. 2). The palatal swelling had
also improved looking less evident. We could not see any evi-
dence of exposed necrotic bone as yet. During a discussion
with the medical oncologist, he was informed of the possibility
of BON and decided not to use zoledronic acid at that time. We
decided to place the patient on a follow-up schedule with peri-
odic visits to the clinic. The patient was instructed to inform us
immediately in case of any changes in the area. We also con-
sidered the occasional use of antibiotic therapy when neces-
sary. The use of chlorhexidine 0.12% mouth rinses bid (two
times/d) was maintained. In the following weeks the patient
was examined and treated occasionally with clindamycin and
twice daily chlorhexidine mouth rinses. This regimen was used
when pain returned and the clinical signs worsened. However,
there was no considerable improvement of the clinical presen-
tation and pain and chronic infection could not be completely
controlled. At this point the patient was referred to a periodon-
tist (EKJM) for evaluation of the periodontal status, the dental
implants, and the possibility of using high intensity laser thera-
py with the objective of associating the antibiotic therapy with
the bacterial reduction effect and anti-inflammatory effect of the
diode and the CO2 lasers. 
Periodontal/Laser treatment
Clinical and radiographic findings related to the periodontium
The patient was seen by the periodontist on June 29, 2006. At
the time the patient presented with spontaneous pain on the
right maxilla, around the area of teeth # 3, 4, and 5. The buccal
and palatal aspects of the posterior right sextant area were
swollen, erythematous, and two fistulas with draining purulent
secretion were detected on buccal, apical of tooth #5 and dis-
tal-buccal of tooth #4. There was generalized plaque accumu-
lation and the gingival tissues presented bleeding upon prob-
ing. On the full mouth periapical radiographs one could ob-
serve mild-moderate horizontal bone loss in the area of implant
#3, teeth #14 and #15. Around the other teeth there were nor-
mal levels of bone crest. Periapical radiolucency was seen in
the area of #5 projected toward the distal to join an area of ra-
diolucency superimposed on the implant of #4 where the bone
destruction seemed to come to the surface in the bone crest.
Periodontal data collection revealed some pseudopockets due
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Figure 2 - Two weeks post clindamycin 300 mg three times /day. Ob-
serve minor improvement of the swelling but persistent draining fistula
(arrow).
to overcountouring of porcelain crowns and true periodontal
pockets ranging from 5 to 7 mm in the upper left quadrant. In
the upper right quadrant pocket depths ranged from 2 mm up
to 8 mm (interproximal between #3 and #4).
Periodontal diagnosis, prognosis and treatment plan
The diagnosis was generalized mild gingivitis; mild to moderate
periodontitis in the area of #14 and #15 with localized moder-
ate to severe periodontitis/peri-implantitis in the upper right
posterior sextant, at the area where BON had been diagnosed. 
Prognosis was generally good but guarded to poor for implant
#4 and tooth #5. However, because of the diagnosis of BON it
was decided that the treatment had to be conservative with the
objective of maintaining the dental implants in the mouth and
avoiding the creation of a large area of exposed necrotic bone.
The periodontal treatment plan was to attempt bacterial reduc-
tion and control of inflammation in area of #3 to #5 with scaling
and root planning, laser therapy, and a routine periodontal
maintenance recall for the rest of the dentition. At this appoint-
ment the proposed treatment plan was discussed with the pa-
tient. He was reassured that the objective of this procedure
was to eliminate local irritants through scaling and root plan-
ning. The laser therapy was to be used as an adjunct with the
goal of achieving improvement of the general health of the gin-
giva and periodontium through reduction of inflammation and
stimulation of fibroblast proliferation. The laser light was also to
be used to reduce the bacterial load and the pain (13-19). Peri-
odontal maintenance recall was also offered to the patient. The
patient agreed with the procedure and signed an informed con-
sent.
The periodontal/laser therapy was initiated immediately with
debridment of the pockets and cleaning of the fistulas. The pa-
tient was given oral hygiene instructions, a Sonicare® powered
toothbrush (Philips, Stamford, CT), and Colgate Total® tooth-
paste (Colgate-Palmolive New York, NY). He was also told to
continue to use chlorhexidine mouth rinses twice daily. On
every of the following appointments the patient received intra-
sulcular debridment and laser therapy of the area of teeth # 3-
5. On the first three sessions a diode laser of 815 nm (Biolase,
Irvine, CA) was used. Treatment was given to the pockets and
the fistulas. The laser parameters to treat periodontal pockets
were: continuous wave (CW); power 1.0 Watt; laser light deliv-
ered through an optic fiber of 400 microns. Pockets 5 mm or
deeper were lased for 15 seconds each and pockets up to 4
mm or less for 10 seconds each. The laser delivery tip was in-
troduced in the pockets parallel to the root surfaces toward api-
cal, stopping 1 mm short of the bottom of the pocket, and
”walked” in the pocket as a periodontal probe. (The operator
used settings following the recommendations of the laser man-
ufacturer). Profuse irrigation with saline solution was used in
the area being treated. Lavage inside the fistulas was also at-
tempted and was done until no more purulent secretion could
be seen. The fistulas were penetrated with the laser probe
about 2 to 4 mm deep. Laser application consisted of gated
wave for 45 seconds (3 × 15 seconds) in each fistula. Profuse
saline irrigation continued throughout laser application. Slow
but continuous improvement of both the pain and the purulent
secretion could be noticed at each presentation. Four weeks
into the treatment the patient returned for follow-up. Whereas
pain was much improved and present only upon palpation of
the area apical of #s 4-5, the fistula more distal to tooth # 4
was increasing in size and still had some purulent secretion. At
this visit, treatment with a CO2 laser of 10,600 nm (Deka Laser,
Fort Lauderdale, FL) was started. CO2 laser was used with the
objective of removing the pocket epithelium and promoting re-
attachment of connective tissue fibers on cementum (20). Bac-
terial reduction can also be achieved. The laser parameters
used were: pulsed wave, power 3.5 Watts, 50 Hz, non contact
(NC). The same parameters were used at the entrance of both
fistulas, in different directions (teeth #3, #4). According to man-
ufacturers’ recommendations, the intrapocket bacterial reduc-
tion procedure was done with pulsed wave, power at 2.8 Watts,
50 Hz, contact mode,16 seconds on the buccal and 16 sec-
onds on the palatal aspect of each tooth, probe 1 mm inside
the pocket, with profuse saline irrigation throughout the proce-
dure. After two more visits the fistula on tooth # 5 had com-
pletely closed (Fig. 3) but the other was still active and enlarg-
ing in size seeming that the two processes had merged becom-
ing one only and located more toward the distal of #4 (Fig. 4).
CO2 laser therapy (same parameters) and local debridment
continued now in two weeks interval. The reachable implant
surfaces were also laser treated with the objective of enhanc-
ing cellular adhesion to the irradiated areas (21-23). By the end
of November 2006 after four more treatment sessions, the pa-
tient presented to the clinic completely asymptomatic and, al-
though now there was clear bone exposure in the area buccal-
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Figure 3 - Four months follow-up when laser therapy and scaling & root
planning of the area had started. Observe significant improvement of
the area but the presence of a small persistent draining fistula (arrow).
Patient has no pain.
Figure 4 - Radiographic appearance 5 months into maintenance thera-
py showing persistent and apparently expanding radiolucent lesion (ar-
row). Pain has not returned.
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distal to tooth # 4 (Fig. 5), there was no more purulent secre-
tion in that opening. The fistula in the area of #5 healed. During
the time the patient received periodontal/laser treatment, he
had to take only one course of amoxicillin/clavulanate potassi-
um 500 mg three times a day for 10 days and never needed to
use analgesics again. Currently, the patient comes to the clinic
for follow-up once a month. He is asymptomatic and has no
longer used antibiotics. Although the necrotic bone is still ex-
posed, the area is maintained with good home care and mouth
rinses with chlorhexidine.
Discussion
The present case illustrates the pitfalls in the management of a
patient with BON. The lack of science-based guidelines for the
management of patients with this disease makes treatment
empiric. Our goal in the present case was to improve quality of
life by controlling the progress of the osteonecrotic process, by
treating infection, and by eliminating the symptoms. Dental ex-
traction and implants removal would have been another alter-
native. However, we decided not to extract teeth # 3-5 to avoid
the formation of a large area of exposed necrotic bone. The
case clearly demonstrates that the pathobiology of the bone
osteonecrotic process associated with the use of bisphospho-
nates still needs elucidation, before we can develop effective
management protocols. Our patient, contrary to most of the
cases reported in the literature, did not have a tooth extraction
as the initiating factor and did not present clinically visible ex-
posed bone (1, 4-6, 8, 9). Therefore, we could not precisely tell
when the process started and making the diagnosis of BON
was difficult. The process of BON probably started due to the
failure of a root canal treatment. However, one can also con-
sider the possibility that the root canal therapy and the paraen-
dodontic surgery failed because the local bone remodeling
process was inhibited by the use of a potent bisphosphonate
and the osteonecrotic process was already in place when the
treatment was done (10). Whether or not the lingering bone re-
modeling suppression caused by the use of risedronate en-
hanced the inability of bone healing remains to be investigated.
Another concern we had prior to making the diagnosis of BON
was to rule out the possibility of metastatic lesion from the
prostate cancer. Prostate cancer is the third most common car-
cinoma to metastasize to the orbit (24). Computerized tomog-
raphy can be used to evaluate the head and neck in these pa-
tients and that was not a concern from the patient’s medical
oncologist (24).
We tried to illustrate that when the diagnosis of BON is made,
before any dental treatment commences, it is important that the
dentist or oral surgeon understand the patient’s current health
status. Discussion of the patient’s health history includes a list
of medications that have been prescribed. Careful questioning
of the patient should address typical lifestyle perspectives: a
post-menopausal woman is likely to have been recommended
to take over-the counter supplemental calcium and vitamin D to
help prevent osteoporosis (5, 9). Often, patients forget to indi-
cate that they are taking a prescription medication such as
zoledronic acid or ibandronate that are taken once a month on-
ly, or even the once a week doses of alendronate or rise-
dronate. Specific questions may be necessary to be asked dur-
ing the questionnaire phase. In some cases, the dentist should
consult with the physician in order to ascertain the complete list
of medications of their common patient.
Patients with multiple myeloma, Paget’s disease or cancers
that have metastasized to the bones are usually treated with in-
travenous bisphosphonates (1, 3). Many of these patients have
bone pain that is alleviated by the treatment, yet the patient
may not always be aware that it is important to let the dentist
know of the medication he or she is taking. 
When a patient develops oral problems during treatment with
bisphosphonates, referral to a dentist who is familiar with treat-
ing BON should be made (oral medicine specialist or oral sur-
geon) (4, 5, 9, 11). The type of bisphosphonate i.e. oral or in-
travenous, the dosage, the duration, and the condition or dis-
ease that is being treated, are all important items to be dis-
cussed. The chronology of symptoms is also important to be
taken into account. 
A common complaint reported, as illustrated by the present
case, is dull to severe pain in the orofacial region. The dentist
should investigate and suspect an odontogenic etiology at first.
The patient may initially have pain that is related to a dental or
periodontal problem, temporomandibular joint dysfunction, or
malignant metastasis to the orofacial region. Abscess forma-
tion may be secondary to a necrotic pulp or infection around
the root, and appropriate dental/periodontal treatment should
be given. However, in many patients, the pain is attributed to a
Figure 5 - 8 months into maintenance therapy. Patient remains asymptomatic. A. Observe through a mirror the buccal surface of the area being treat-
ed with laser therapy and local plaque debridment. Observe that there is now clear evidence of necrotic bone exposure, characterizing stage II BON.
However the area is clean and there is no evidence of pus (arrow). B. Radiographic appearance of the same area showing signs of improvement,
with apparent better calcification in the area (arrows).
A B
“bad tooth” that is treated by surgical extraction, and subse-
quently an area of BON develops (6). If the patient is taking a
bisphosphonate, the possibility that the symptoms are truly
from the BON must be considered. Some patients complain
about a rough area on the gingival soft tissues that is irritating
the tongue, buccal mucosa or labial mucosa as the first symp-
tom (5, 9, 11). This is likely to be the exfoliation of a section of
necrotic bone that is coming through the mucosa and trauma-
tizing adjacent tissue. These areas of mucosa are subject to in-
fections due to the oral microflora, becoming quite painful.
Spontaneous development of BON without tooth extraction
may be due to microfractures in the jaws that are not able to
heal because of the bisphosphonate medications (10).   
Treatment of BON: The goals of treatment of BON are to elimi-
nate pain and infection and to prevent the loss of additional
bone (9, 25). We followed these guidelines to manage the case
here reported. Although we may have felt tempted to remove
the involved dental implant, the institution of laser therapy as
an adjunct to local periodontal debridment, as well as good
home maintenance performed by the patient, prevented the
process from progression. Therefore, oral function and appear-
ance could be preserved without risking the formation of a larg-
er necrotic bone defect that is easily infected and difficult to
maintain. As demonstrated in the present case, while BON ap-
pears clinically and radiographically similar to osteomyelitis, the
treatment of BON can focus on non-surgical intervention. Sys-
temic antibiotics and chlorhexidine mouthwash should be pre-
scribed. Oral prophylaxis and good home care should be ac-
complished to reduce the bacterial burden. Where rough areas
of bone are irritating other tissue, the bone should be
smoothed with a dental handpiece or, if available, removed
with a laser light (1, 26), or else covered by a removable appli-
ance that does not put any pressure on the bone or surround-
ing soft tissue (11). Frequent re-evaluation should be planned
until the acute symptoms are resolved. In some cases, atrau-
matic removal of the necrotic bone should be accomplished. In
addition, as it was demonstrated in this case, high intensity
laser pocket disinfection can be used effectively. Although we
have only a one-year follow-up in this case, one could see that
laser therapy was important in achieving pain control and infec-
tion control, preventing the patient from constantly taking
painkillers and antibiotics. Although this information comes
from personal observation, it may present a new alternative for
the chronic management of BON. Lasers may be expensive
devices but when available to the well-trained dentist, the laser
light can assist in improving patient care in dentistry.
It has been recommended that no further elective invasive pro-
cedures (surgery that involves the bone) should be performed
in patients with BON (5, 6, 9, 11, 25). However, in more ad-
vanced cases, aggressive surgical management may become
an option. However, long-term controlled studies with larger
populations are necessary. Non-surgical endodontic therapy
may be substituted for extraction of teeth (27).
Finally, dentists have been tempted to ask their patients to dis-
continue bisphosphonate therapy. We believe that this practice
should never be done. If a patient is taking a bisphosphonate
there is a medical reason for it. Most of the patients being seen
in the dental offices are those with osteoporosis and osteope-
nia. It is recommended that the dentist consult with the physi-
cian to what is appropriate to consider as alternative treatments
(4). The risk involved in the discontinuation of an oral bisphos-
phonate for a patient with osteoporosis includes hip fracture. It
is known that hip fracture is associated with high mortality. The
reported range of death 1 year after hip fracture is 20 to 25%
(28). One must consider that even when a patient on bisphos-
phonate therapy develops BON, treatment outcomes are rea-
sonable, as it has been demonstrated in this case report.
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